DNA*

Total Rating:
0 / 0

1 Comment

    • Wed Dec 26th 05:53 AM | Rating: 0 0
      Commented on:
      Is it Time to Run Away from Merck?
      I agree with your analysis of Merck's cannabinoid receptor antagonist. But the cholesterol drug that they plan to file for marketing approval is Cordaptive (a niacin drug) rather than anaceptrapib (their CETP inhibitor). Cordaptive is nothing like Pfizer's torcetrapib. Would this change your outlook for Merck?
      View article »
Contribute an Article Become a Seeking Alpha Contributor